The purpose of this clinical study is to compare the effectiveness and safety of an investigational drug (lanifibranor, which will be given as an oral pill taken each day), as a potential long-term treatment option for those living with NASH and liver fibrosis stage 2 or 3. Lanifibranor is a pan-peroxisome proliferator-activated receptor (PanPPAR) agonist, an investigational drug with the potential to address metabolic and histological aspects of NASH, including possible decrease in triglycerides and increase of HDL (good) cholesterol.
You may be eligible to participate if you:
• Are 18 years or older
• Have been diagnosed with non-alcoholic steatohepatitis (NASH) with liver fibrosis